Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Approach to the treatment-naïve patient with HCV genotype 1 infection.

Infectious disease clinics of North America - 1 Dec 2012

Muir Andrew J

Abstract excerpt

In May 2011, the protease inhibitors boceprevir and telaprevir were approved in combination with peginterferon-α and ribavirin for the treatment of genotype 1 chronic hepatitis C virus infection in the United States. These regimens brought substantial improvements in sustained virologic response rates, especially for treatment-naïve patients. This article reviews the approach to therapy with these genotype 1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Algorithms
Share to Antiviral Agents
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to RNA, Viral

Share to Viral Load

Source

Identifiers

PMID: 23083822
DOI: 10.1016/j.idc.2012.08.012

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Approach to the treatment-naïve patient with HCV genotype 1 infection.PMID 23083822Read ↗

Therapeutic approach to the treatment-naive patient with hepatitis C virus genotype 1 infection: a step-by-step approach.Semantic proximity Read ↗

Approach to the treatment-experienced patient with hepatitis C virus genotype 1 infection.Semantic proximity Read ↗

Management of the treatment-experienced patient infected with hepatitis C virus genotype 1: options and considerations.Semantic proximity Read ↗

Optimal therapy in genotype 1 patients.Semantic proximity Read ↗

Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.Semantic proximity Read ↗

Hepatitis C therapy update.Semantic proximity Read ↗

Treatment Considerations for Unique Patient Populations With HCV Genotype 1 Infection.Semantic proximity Read ↗

UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients.Semantic proximity Read ↗

Current and Evolving Treatments of Genotype 1 Hepatitis C Virus.Semantic proximity Read ↗

Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?Semantic proximity Read ↗

Advances in the management of hepatitis C.Semantic proximity Read ↗

Importance of HCV genotype 1 subtypes for drug resistance and response to therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.